DEF: Cardiff Oncology 2026 Annual Meeting Proxy Statement

Cardiff Oncology, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and an increase in equity incentive plan shares.

Summary

• The company will hold its Annual Meeting of Stockholders on June 11, 2026, in San Diego, CA.
• Stockholders will vote on the election of six directors, ratification of BDO USA, P.C. as the independent auditor for 2026, and an amendment to the 2021 Omnibus Equity Incentive Plan.
• The proposed amendment to the 2021 Plan seeks to increase the authorized shares issuable thereunder by 3,000,000, bringing the total to 15,150,000 shares.
• The company is also seeking an advisory vote on the compensation of its named executive officers.
• As of the April 20, 2026 record date, there were 68,369,896 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine governance filing for an annual meeting, reflecting standard operational and compensation adjustments for a clinical-stage biotech company.

Positives

• The company maintains a strong commitment to good corporate governance, including the separation of the CEO and Board Chair roles.
• The company has successfully secured a new U.S. patent (No. 12,263,173) for onvansertib in combination with bevacizumab, with an expiration date no earlier than 2043.
• Clinical trial data from the Phase 2 CRDF-004 trial showed a 49% confirmed objective response rate in the 30mg onvansertib dose arm compared to 30% in the control arm.
• The company has a clear, non-evergreen equity incentive plan with no tax gross-ups and a minimum one-year vesting period for awards.

Negatives

• The company remains a pre-revenue, clinical-stage biotechnology firm with significant net losses.
• The proposed increase in the equity incentive plan will result in additional dilution to existing stockholders.
• The company experienced a leadership transition in early 2026, with the former CEO and CFO stepping down.

Risks

• The company faces intense competition in the biotechnology sector for talent and capital.
• The company's ability to execute its corporate strategy and retain personnel is dependent on its ability to grant equity awards.
• The company's financial results are subject to risks inherent in clinical-stage drug development, including regulatory and clinical trial outcomes.
• The company's equity incentive plan reserve is expected to support only one to two years of grants, necessitating potential future share increases.

Future Outlook

The company intends to continue advancing its lead clinical program, onvansertib, through disciplined execution of development activities and regulatory engagement, while focusing on long-term value creation through intellectual property and corporate planning.

Management Comments

• The Board believes the proposed share increase is reasonable and mindful of equity dilution.
• The Board believes the separation of the CEO and Chair roles enhances accountability and strengthens independence.
• The Compensation Committee believes that stock options represent an efficient method of linking executive and stockholder experiences.

Industry Context

StockSavvy.ai notes that Cardiff Oncology's request for additional equity pool shares is consistent with broader trends in the clinical-stage biotechnology sector, where companies must balance the need to attract and retain specialized talent with the necessity of managing shareholder dilution.

Comparison to Industry Standards

• The company's potential equity dilution of 28.9% is positioned below the 50th percentile (30.0%) of comparable Life Sciences companies with market caps between $100M and $300M.
• The company's share request of 4.4% dilution is well below the 50th percentile (7.3%) of comparable Life Sciences companies that requested equity pool increases in 2025.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders will be asked to vote on proposals that may impact future dilution and executive compensation.
• Employees and directors are eligible for equity awards under the proposed plan amendment.

Next Steps

• Hold the Annual Meeting of Stockholders on June 11, 2026.
• Tabulate votes for the election of directors and the approval of the equity plan amendment.
• File a Form 8-K with the SEC within four business days after the Annual Meeting to report final voting results.

Key Dates

Keywords

Cardiff Oncology, CRDF, onvansertib, biotechnology, oncology, proxy statement, equity incentive plan, clinical trials